A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis

Exclusion Criteria

• •Participants are excluded from the study if any of the following criteria apply:
• •Participants with active Crohn's Disease (CD), indeterminate colitis or microscopic colitis
• •Participants with fecal sample positive for culture/ova for aerobic pathogens or positive for Clostridium difficile B toxin in stools
• •Participant with ostomy or ileoanal pouch, prior colectomy or anticipated colectomy during their participation in the study
• •Participants with the following ongoing known complications of UC: fulminant disease, toxic megacolon or colonic dysplasia except for adenoma
• •Participants with intestinal failure or short bowel syndrome requiring Total Parenteral Nutrition
• •History of recurrent or recent serious infection within 4 weeks of screening, or infection(s) requiring hospitalization or treatment with IV anti-infectives within 30 days prior to baseline, or infections(s) requiring oral anti-infectives within 14 days prior to baseline, except as required as part of an anti-Tuberculosis (TB) regimen
• •Known history of or suspected significant current immunosuppression.
• •History or solid organ transplant or splenectomy
• •History of moderate to severe congestive heart failure (New York Health Association Class III or IV), or recent cerebrovascular accident.
• •History of demyelinating disease (including myelitis) or neurologic symptoms suggestive of demyelinating disease
• •Participants with a history of malignancy or lymphoproliferative disease other than adequately treated localized carcinoma in situ of the cervix or nonmetastatic squamous cell carcinoma, or nonmetastatic basal cell carcinoma of the skin
• •Participants with a diagnosis of inflammatory conditions other than UC (including but not limited to systemic lupus erythematosus, systemic sclerosis, myositis, rheumatoid arthritis, primary biliary cirrhosis, multiple sclerosis, Behcet's disease, sarcoidosis, etc.)
• •History of Human Immunodeficiency Virus (HIV) infection or positive HIV serology at Screening
• •History of Interstitial Lung Disease
• •Participants with any of the following results at Screening:
• •* Positive (or indeterminate) Hepatitis B surface antigen (HBs Ag) or,
• •* Positive total Hepatitis B core antibody (anti-HBc) confirmed by positive Hepatitis B Virus (HBV) Deoxyribonucleic acid (DNA) or,
• •* Positive Hepatitis C Virus (HCV) antibody
• •Screening laboratory and other analyses showing abnormal results
• •History of any other condition which, in the opinion of the Investigator, would put the participant at risk by participation in the protocol
• •The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.